Literature DB >> 8144402

A new serum tumor marker, CAM 123-6, highly specific to pulmonary adenocarcinoma.

H Hamada1, N Kohno, K Hiwada.   

Abstract

KL-6, a circulating mucin-like glycoprotein, is a pulmonary adenocarcinoma-associated antigen and is also regarded as an indicator of disease activity of interstitial pneumonitis. KL-6 has extensive heterogeneous antigenic determinants and consists of multiple heterogeneous antigen molecules. We have searched for circulating KL-6-associated glycoproteins with superior diagnostic value to KL-6 as a tumor marker for pulmonary adenocarcinoma. A new murine monoclonal antibody EH-123 reacting with an asialosugar chain on KL-6 was established. A new KL-6-associated molecule detected by a bimonoclonal bideterminant sandwich assay using the EH-123 antibody as a catcher and horseradish peroxidase-labeled KL-6 as a tracer was designated as CAM 123-6. In 59% (22 of 37) of patients with pulmonary adenocarcinoma, serum levels of CAM 123-6 were abnormally elevated and the positive rate increased with the progression of clinical stage. Elevated levels were not detected in normal individuals or in patients with benign lung diseases, other histologic types of lung cancer, gastric cancer, colon cancer or breast cancer. CAM 123-6 was more specific to pulmonary adenocarcinoma than carcinoembryonic antigen (CEA), but the sensitivity of CAM 123-6 for pulmonary adenocarcinoma was similar to that of CEA. CAM 123-6 is a promising candidate as a serum tumor marker for pulmonary adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8144402      PMCID: PMC5919420          DOI: 10.1111/j.1349-7006.1994.tb02084.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  32 in total

1.  Circulating antigen KL-6 and lactate dehydrogenase for monitoring irradiated patients with lung cancer.

Authors:  N Kohno; H Hamada; S Fujioka; K Hiwada; M Yamakido; M Akiyama
Journal:  Chest       Date:  1992-07       Impact factor: 9.410

2.  [A statistical analysis of serum sialyl Lewis X-1 (SLX), CEA, SCC and NSE levels in patients with lung cancer].

Authors:  H Ueoka; T Ohnoshi; T Moritaka; K Kiura; Y Mima; T Horiguchi; Y Segawa; M Tabata; T Shibayama; T Maeda
Journal:  Nihon Kyobu Shikkan Gakkai Zasshi       Date:  1991-08

3.  A novel method for screening monoclonal antibodies reacting with antigenic determinants on soluble antigens; a reversed indirect-enzyme linked immunosorbent assay (RI-ELISA).

Authors:  N Kohno; M Akiyama; S Kyoizumi; M Tanabe; T Oyama; M Yamakido
Journal:  Hiroshima J Med Sci       Date:  1987-12

4.  Suppression of cellular aggregation by high levels of episialin.

Authors:  M J Ligtenberg; F Buijs; H L Vos; J Hilkens
Journal:  Cancer Res       Date:  1992-04-15       Impact factor: 12.701

5.  Assessment of serial carcinoembryonic antigen (CEA) assays in postoperative detection of recurrent colorectal cancer.

Authors:  P H Sugarbaker; N Zamcheck; F D Moore
Journal:  Cancer       Date:  1976-12       Impact factor: 6.860

6.  A circulating heat-resistant mucin-like antigen in patients with lung-cancer detected by a new murine monoclonal-antibody.

Authors:  N Kohno; M Miyake; Y Inoue; A Yokoyama; K Hiwada; M Tanabe; M Yamakido; S Kyoizumi; M Akiyama
Journal:  Int J Oncol       Date:  1992-11       Impact factor: 5.650

7.  Carcinoembryonic antigen in 228 patients with carcinoma of the lung.

Authors:  R G Vincent; T M Chu; T B Fergen; M Ostrander
Journal:  Cancer       Date:  1975-12       Impact factor: 6.860

8.  Heterogeneity of mucin gene expression in normal and neoplastic tissues.

Authors:  S B Ho; G A Niehans; C Lyftogt; P S Yan; D L Cherwitz; E T Gum; R Dahiya; Y S Kim
Journal:  Cancer Res       Date:  1993-02-01       Impact factor: 12.701

9.  Gastrointestinal cancer-associated antigen in immunoperoxidase assay.

Authors:  B F Atkinson; C S Ernst; M Herlyn; Z Steplewski; H F Sears; H Koprowski
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

10.  Monoclonal antibody reactive with the sialyl-sugar residue of a high molecular weight glycoprotein in sera of cancer patients.

Authors:  S Hirohashi; M Watanabe; Y Shimosato; T Sekine
Journal:  Gan       Date:  1984-06
View more
  2 in total

1.  Serum KL-6 levels in patients with pulmonary complications after allogeneic bone marrow transplantation.

Authors:  T Ashida; M Higashishiba; Y Sumimoto; T Sano; H Miyazato; T Shimada; J Miyatake; K Kawanishi; Y Tatsumi; A Kanamaru
Journal:  Int J Hematol       Date:  2001-12       Impact factor: 2.490

2.  Radioimmunoscintigraphy of pancreatic cancer in tumor-bearing athymic nude mice using (99m)technetium-labeled anti-KL-6/MUC1 antibody.

Authors:  Kenji Matsumura; Ichiro Niki; Hui Tian; Masahisa Takuma; Norio Hongo; Shunro Matsumoto; Hiromu Mori
Journal:  Radiat Med       Date:  2008-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.